Nyxoah (NYXH) Income from Continuing Operations (2021 - 2026)
Nyxoah (NYXH) posted quarterly Income from Continuing Operations of 18210234.43 for Q1 2026, down 22.23% year-over-year from 23414027.23 in Q1 2025, and down 99.93% quarter-over-quarter from 25286517269.8 in Q4 2025.
Nyxoah (NYXH) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Nyxoah's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 18210234.43 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 22.23% year-over-year to 18210234.43; the TTM figure through Mar 2026 stood at 25309596899.58 (up 282.73% YoY), while the FY2025 annual figure was 105792930.79, down 61.6% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 18210234.43, down from 25286517269.8 in the prior quarter.
- The five-year high for Income from Continuing Operations was 25286517269.8 in Q4 2025, with the low at 13879985652.71 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 6291631.82 (2022), against an average of 1499296197.8.
- Peak annual rise in Income from Continuing Operations reached 181341.41% in 2023, while the deepest fall reached 308.84% in 2023.
- Nyxoah's Income from Continuing Operations stood at 13565208968.99 in 2022, then slumped by 191.57% to 12421726249.19 in 2023, then decreased by 11.74% to 13879985652.71 in 2024, then jumped by 282.18% to 25286517269.8 in 2025, then plunged by 99.93% to 18210234.43 in 2026.
- Business Quant data shows NYXH's Income from Continuing Operations at 18210234.43 in Q1 2026, 25286517269.8 in Q4 2025, and 27566319.05 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 452.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 383.43 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 139.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 93.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 135.00 Mn |
| 10 | Nyxoah | 90.94 Mn | 90.94 Mn | 5.33 Mn | -38.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.51 Mn |
| Mar 31, 2026 | 18.21 Mn |
| Dec 31, 2025 | 25.29 Bn |
| Sep 30, 2025 | 27.57 Mn |
| Jun 30, 2025 | -22.70 Mn |
| Mar 31, 2025 | 23.41 Mn |
| Dec 31, 2024 | -13.88 Bn |
| Sep 30, 2024 | 18.73 Mn |
| Jun 30, 2024 | -13.18 Mn |
| Mar 31, 2024 | 132.31 Mn |
| Dec 31, 2023 | -12.42 Bn |
| Sep 30, 2023 | -13.14 Mn |
| Jun 30, 2023 | -11.91 Mn |
| Mar 31, 2023 | 12.78 Bn |
| Dec 31, 2022 | 13.57 Bn |
| Sep 30, 2022 | 6.29 Mn |
| Jun 30, 2022 | -5.10 Mn |
| Mar 31, 2022 | -7.05 Mn |
| Dec 31, 2021 | 7.15 Bn |
| Sep 30, 2021 | -10.01 Mn |